BioPass Pharma is developing a revolutionary formulation intended for the treatment of brain or CNS diseases utilizing its patented novel technology, which is designed to deliver molecules directly into the brain by bypassing the BBB. Its novel nasal formulation offers short onset of a non-invasive, painless, easily administered treatment, avoiding gastrointestinal and hepatic presystemic metabolism. BioPass Pharma has secured exclusive rights for this technology from the Hebrew University of Jerusalem.